Status:
UNKNOWN
Safety, Efficacy of BNT162b2 mRNA Vaccine in CLL
Lead Sponsor:
Bnai Zion Medical Center
Collaborating Sponsors:
Ziv Medical Center
Hadassah Medical Organization
Conditions:
Chronic Lymphocytic Leukemia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
On behalf of the Israel CLL study group the investigators will evaluate the efficacy and safety of BNT162b2 mRNA Covid-19 Vaccine in patients with chronic lymphocytic leukemia
Eligibility Criteria
Inclusion
- Diagnosis of CLL was according to the IWCLL criteria
- All patients received two 30-μg doses of BNT162b2, administered intramuscularly 3 weeks apart. (Pfizer).
Exclusion
- previous covid19 virus infection
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2022
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT04862806
Start Date
February 1 2021
End Date
March 1 2022
Last Update
September 17 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Bnai Zion Medical Center
Haifa, Israel, 31048
2
Hematology Division, Chaim Sheba Medical Center
Tel Aviv, Israel